Literature DB >> 17363566

Inactivation of Apc in the mouse prostate causes prostate carcinoma.

Katia J Bruxvoort1, Holli M Charbonneau, Troy A Giambernardi, James C Goolsby, Chao-Nan Qian, Cassandra R Zylstra, Daniel R Robinson, Pradip Roy-Burman, Aubie K Shaw, Bree D Buckner-Berghuis, Robert E Sigler, James H Resau, Ruth Sullivan, Wade Bushman, Bart O Williams.   

Abstract

Alterations of the Wnt/beta-catenin signaling pathway are positively associated with the development and progression of human cancer, including carcinoma of the prostate. To determine the role of activated Wnt/beta-catenin signaling in mouse prostate carcinogenesis, we created a mouse prostate tumor model using probasin-Cre-mediated deletion of Apc. Prostate tumors induced by the deletion of Apc have elevated levels of beta-catenin protein and are highly proliferative. Tumor formation is fully penetrant and follows a consistent pattern of progression. Hyperplasia is observed as early as 4.5 weeks of age, and adenocarcinoma is observed by 7 months. Continued tumor growth usually necessitated sacrifice between 12 and 15 months of age. Despite the high proliferation rate, we have not observed metastasis of these tumors to the lymph nodes or other organs. Surgical castration of 6-week-old mice inhibited tumor formation, and castration of mice with more advanced tumors resulted in the partial regression of specific prostate glands. However, significant areas of carcinoma remained 2 months postcastration, suggesting that tumors induced by Apc loss of function are capable of growth under conditions of androgen depletion. We conclude that the prostate-specific deletion of Apc and the increased expression of beta-catenin associated with prostate carcinoma suggests a role for beta-catenin in prostate cancer and offers an appropriate animal model to investigate the interaction of Wnt signaling with other genetic and epigenetic signals in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363566     DOI: 10.1158/0008-5472.CAN-06-3028

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

Review 1.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

2.  Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Authors:  Srinivas Nandana; Manisha Tripathi; Peng Duan; Chia-Yi Chu; Rajeev Mishra; Chunyan Liu; Renjie Jin; Hironobu Yamashita; Majd Zayzafoon; Neil A Bhowmick; Haiyen E Zhau; Robert J Matusik; Leland W K Chung
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

Review 3.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

4.  Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Authors:  Xiuping Yu; Yongqing Wang; Ming Jiang; Brian Bierie; Pradip Roy-Burman; Michael M Shen; Makoto Mark Taketo; Marcia Wills; Robert J Matusik
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

5.  Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

Authors:  Daxing Xie; Crystal Gore; Jun Liu; Rey-Chen Pong; Ralph Mason; Guiyang Hao; Michael Long; Wareef Kabbani; Luyang Yu; Haifeng Zhang; Hong Chen; Xiankai Sun; David A Boothman; Wang Min; Jer-Tsong Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

6.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

7.  Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Authors:  Jeffrey C Francis; Afshan McCarthy; Martin K Thomsen; Alan Ashworth; Amanda Swain
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

8.  Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling.

Authors:  Xiaohong Li; Yongqing Wang; Ali-Reza Sharif-Afshar; Consolate Uwamariya; Andrew Yi; Kenichiro Ishii; Simon W Hayward; Robert J Matusik; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-10-25       Impact factor: 3.880

Review 9.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

Review 10.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.